CASADEI, CHIARA
 Distribuzione geografica
Continente #
AS - Asia 2.320
NA - Nord America 1.069
EU - Europa 721
Continente sconosciuto - Info sul continente non disponibili 126
SA - Sud America 83
AF - Africa 54
OC - Oceania 3
Totale 4.376
Nazione #
US - Stati Uniti d'America 1.012
VN - Vietnam 850
SG - Singapore 440
CN - Cina 399
HK - Hong Kong 274
IT - Italia 241
DE - Germania 200
BD - Bangladesh 129
KR - Corea 78
FR - Francia 64
BR - Brasile 53
NL - Olanda 48
IN - India 38
CA - Canada 35
SE - Svezia 32
FI - Finlandia 29
JP - Giappone 27
PH - Filippine 17
RU - Federazione Russa 17
CI - Costa d'Avorio 15
GB - Regno Unito 15
ID - Indonesia 14
AT - Austria 12
GH - Ghana 12
IE - Irlanda 12
TH - Thailandia 12
PL - Polonia 11
SC - Seychelles 10
AR - Argentina 9
CO - Colombia 9
MX - Messico 8
BE - Belgio 7
GR - Grecia 7
JM - Giamaica 6
TR - Turchia 6
TW - Taiwan 6
CH - Svizzera 5
TN - Tunisia 5
ZA - Sudafrica 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
ES - Italia 4
IQ - Iraq 4
SA - Arabia Saudita 4
VE - Venezuela 4
AU - Australia 3
JO - Giordania 3
PK - Pakistan 3
BB - Barbados 2
BG - Bulgaria 2
DK - Danimarca 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
MD - Moldavia 2
MY - Malesia 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
TG - Togo 2
UA - Ucraina 2
AZ - Azerbaigian 1
BS - Bahamas 1
BY - Bielorussia 1
CL - Cile 1
CR - Costa Rica 1
DM - Dominica 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
KE - Kenya 1
KZ - Kazakistan 1
LT - Lituania 1
MM - Myanmar 1
MU - Mauritius 1
NG - Nigeria 1
NI - Nicaragua 1
NP - Nepal 1
PE - Perù 1
PT - Portogallo 1
PY - Paraguay 1
SN - Senegal 1
SR - Suriname 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TZ - Tanzania 1
Totale 4.250
Città #
Singapore 326
Ho Chi Minh City 248
Hong Kong 243
San Jose 233
Hanoi 216
Hefei 165
Ashburn 109
Council Bluffs 86
Los Angeles 81
Seoul 72
Bologna 51
Santa Clara 50
New York 49
Krefeld 41
Da Nang 40
Lauterbourg 35
Milan 30
Haiphong 28
Beijing 26
Buffalo 24
Boardman 23
Tokyo 19
Rome 18
São Paulo 17
Bengaluru 16
Abidjan 15
Amsterdam 15
Bad Bellingen 15
Hải Dương 15
Lappeenranta 15
Chicago 13
Ha Long 13
Helsinki 13
Can Tho 12
Dublin 12
Accra 11
Biên Hòa 11
Frankfurt am Main 11
Munich 11
Toronto 11
Thái Nguyên 10
Dallas 9
Jakarta 9
Shanghai 9
Falkenstein 8
Nuremberg 8
Vienna 8
Casalecchio di Reno 7
Naples 7
Nha Trang 7
Ninh Bình 7
Thái Bình 7
Warsaw 7
Des Moines 6
Vũng Tàu 6
Athens 5
Brescia 5
Brooklyn 5
Bắc Giang 5
Düsseldorf 5
Guangzhou 5
Hillsboro 5
Houston 5
Kingston 5
Mexico City 5
Modena 5
Montreal 5
Moscow 5
Phoenix 5
Quảng Ngãi 5
San Francisco 5
Southend 5
Turin 5
Tân Tiến 5
Bangkok 4
Brussels 4
Chandler 4
Charlotte 4
Cleveland 4
Genoa 4
Huế 4
Hyderabad 4
Princeton 4
Quảng Ninh 4
Quận Phú Nhuận 4
Ravenna 4
Rio de Janeiro 4
Salt Lake City 4
Shaoxing 4
Tongling 4
Wilmington 4
Zhengzhou 4
Ân Thi 4
Acalanes Ridge 3
Amman 3
Bern 3
Bến Tre 3
Caracas 3
Fort Worth 3
Foshan 3
Totale 2.746
Nome #
Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants 358
Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer 290
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer 216
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 203
Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure 156
Immune modulation in prostate cancer patients treated with androgen receptor (Ar)-targeted therapy 134
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment 128
Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology 122
Immunosenescence in Testicular Cancer Survivors: Potential Implications of Cancer Therapies and Psychological Distress 121
Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC) 116
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer 115
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer 108
Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy 103
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide 101
Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial 94
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer 93
Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives 88
Development of a Prognostic Model for Early Breast Cancer Integrating Neutrophil to Lymphocyte Ratio and Clinical-Pathological Characteristics 88
Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial 87
The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer 87
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study 86
Correlation of [68Ga]Ga-PSMA PET/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective study 79
Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors 79
Perspectives, Challenges, and Advances in Therapeutic Strategies for Gynecological Malignant Tumors 74
Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia related to PARP inhibitor Maintenance Line in Real-world Ovarian Cancer Patients 70
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 67
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer 65
Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions 64
Human chorionic gonadotropin–positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3) 63
ROLE OF HPV VACCINATION AFTER CARCINOMA IN SITU OF CERVIX UTERI (CIN) IN REAL-WORLD PATIENTS 60
The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer 60
Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA 57
Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer 56
Immune-checkpoint inhibitors and the importance of concomitant medications: focus on antibiotics 53
Hormonal Therapy For Endometriosis And The Risk Of Endometriosis-Associated Gynecologic Cancers: A Propensity Score-Adjusted Real-World Data Study 52
Germline BRCA-mutated metastatic breast cancer with positive hormone receptor 51
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients 44
Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough? 44
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) 40
Psychosocial issues in long-term survivors of testicular cancer 40
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation 37
High-dose chemotherapy in a patient with coronavirus disease (COVID-19) 36
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis 35
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study 30
Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immuno-oncology: A real-world study on behalf of Meet-URO group (MeetUro-7b) 29
Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy 23
Aeromonas veronii biovar veronii and sepsis-infrequent complication of biliary drainage placement: A case report 21
The prognostic role of haemoglobin in patients undergoing concurrent chemo-radiation for anal cancer 20
Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors 19
Therapeutic challenges for cisplatin-resistant ovarian germ cell tumors 19
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 19
Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review 19
Artificial intelligence for predicting pathological complete response to neoadjuvant therapy in triple-negative breast cancer: A systematic review and meta-analysis 17
Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer 17
Biomimetic organo-specific scaffolds reveal lineage-specific adaptations of breast cancer cells in bone metastasis 12
Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice 11
Totale 4.376
Categoria #
all - tutte 9.911
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.911


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202236 0 0 1 4 3 2 0 2 2 5 10 7
2022/202352 2 6 2 4 3 11 1 1 9 4 3 6
2023/2024210 2 3 0 2 0 6 4 2 167 11 9 4
2024/2025555 30 63 42 52 49 31 14 27 3 42 52 150
2025/20263.259 366 189 140 142 125 42 826 199 586 245 256 143
2026/2027256 96 160 0 0 0 0 0 0 0 0 0 0
Totale 4.376